Detailed company information
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2024 - Q2Released: May 06, 2024
Earnings Transcript for 2024 - Q1Released: Feb 07, 2024
Earnings Transcript for 2023 - Q4Released: Nov 20, 2023
Earnings Transcript for 2023 - Q3Released: Aug 07, 2023
Earnings Transcript for 2023 - Q2Released: May 08, 2023
Earnings Transcript for 2023 - Q1Released: Feb 07, 2023
Earnings Transcript for 2022 - Q4Released: Nov 21, 2022
Earnings Transcript for 2022 - Q3Released: Aug 08, 2022
Earnings Transcript for 2022 - Q2Released: May 09, 2022
Earnings Transcript for 2022 - Q1Released: Feb 08, 2022
Earnings Transcript for 2021 - Q4Released: Nov 22, 2021
Earnings Transcript for 2021 - Q3Released: Aug 08, 2021
Earnings Transcript for 2021 - Q2Released: May 10, 2021
Earnings Transcript for 2021 - Q1Released: Feb 08, 2021
Earnings Transcript for 2020 - Q4Released: Nov 23, 2020
Earnings Transcript for 2020 - Q3Released: Aug 05, 2020
Earnings Transcript for 2020 - Q2Released: May 07, 2020
Earnings Transcript for 2020 - Q1Released: Feb 06, 2020
Earnings Transcript for 2019 - Q4Released: Nov 21, 2019
Earnings Transcript for 2019 - Q3Released: Aug 06, 2019
Earnings Transcript for 2019 - Q2Released: May 07, 2019
Earnings Transcript for 2019 - Q1Released: Feb 06, 2019
CCCC C4 Therapeutics, Inc.
Dafinchi
